Necrotising enterocolitis (NEC) is a disease that affects the small and large intestine of premature babies. It is characterized by inflammation and tissue death in parts of the intestines. NEC most commonly occurs in very premature and low birth weight infants. It develops when portions of the bowels tissue become inflamed and die, leading to perforations in the intestines that allow its contents to spill into the abdomen. This life-threatening condition requires urgent surgical or medical intervention. The leading cause of NEC is believed to be an immature gastrointestinal system of the premature infant that causes them to be susceptible to invasion of bacteria and infection.
The Necrotising Enterocolitis Market is estimated to be valued at US$ 7.10 billion in 2024 and is expected to exhibit a CAGR of 5.6% over the forecast period 2024-2031.
Increasing cases of preterm births have significantly contributed to the growing demand for treatment and management of NEC in neonates. Premature babies born before 37 weeks gestation usually suffer from digestive and immunological immaturity which increases the chances of developing NEC. Moreover, inadequate breastfeeding of preterm new borns also acts as a risk factor.
Key Takeaways
Key players operating in the necrotising enterocolitis market are AbbVie, AstraZeneca, Baxter International, Bristol-Myers Squibb, and Fresenius Kabi.
Growing number of preterm births worldwide is a key factor fueling the demand for targeted treatment and management of NEC. According to WHO, preterm birth complications are the leading cause of death among children under 5 years of age, with approximately 1 million children dying each year due to preterm birth complications.
Major companies are expanding their presence in developing markets like Asia Pacific and Latin America to leverage high growth opportunities in these regions. The market is also witnessing increasing collaboration between players to develop innovative drugs and therapies for NEC.
Market Key Trends
One major trend gaining traction in the necrotising enterocolitis market is the adoption of antibiotic prophylaxis for premature infants. Research studies have shown administering oral antibiotics like gentamicin to preterm newborns reduces the chances of developing NEC by arresting bacterial overgrowth in the intestines. Companies are engaged in developing new antibiotic formulations specifically designed for preterm and low birth weight infants. With rising prematurity cases globally, prophylactic use of antibiotics is expected to emerge as an important preventive strategy for NEC in the coming years.
Porter’s Analysis
Threat of new entrants: Low startup costs in the NEC market attract new companies but the presence of large players make market competition intense.
Bargaining power of buyers: Buyers have moderate bargaining power due to the availability of substitute products and services. However, specialized medical products have lesser substitutes.
Bargaining power of suppliers: The suppliers of raw materials have moderate bargaining power due to the availability of alternative supplier options and suppliers are large in number.
Threat of new substitutes: Substitute threats are low as there are limited treatment options available for NEC.
Competitive rivalry: The presence of large multinational companies results in high competitive rivalry in the NEC market.
Geographical Regions
North America holds the largest share in the necrotising enterocolitis market, owing to the developments in healthcare infrastructure and availability of advanced treatment options. The United States dominates the North American as well as global necrotising enterocolitis market.
The Asia Pacific region is expected to witness the highest growth over the forecast period due to increasing birth rates, rising healthcare expenditure, growing awareness about NEC, and improving medical facilities. Various initiatives by public and private players also support the market growth.
What Are The Key Data Covered In This Necrotising Enterocolitis Market Report?
:- Market CAGR throughout the predicted period
:- Comprehensive information on the aspects that will drive the Necrotising Enterocolitis Market’s growth between 2024 and 2031.
:- Accurate calculation of the size of the Necrotising Enterocolitis Market and its contribution to the market, with emphasis on the parent market
:- Realistic forecasts of future trends and changes in consumer behaviour
:- Necrotising Enterocolitis Market Industry Growth in North America, APAC, Europe, South America, the Middle East, and Africa
:- A complete examination of the market’s competitive landscape, as well as extensive information on vendors
:- Detailed examination of the factors that will impede the expansion of Necrotising Enterocolitis Market vendors
FAQ’s
Q.1 What are the main factors influencing the Necrotising Enterocolitis Market?
Q.2 Which companies are the major sources in this industry?
Q.3 What are the market’s opportunities, risks, and general structure?
Q.4 Which of the top Necrotising Enterocolitis Market companies compare in terms of sales, revenue, and prices?
Q.5 Which businesses serve as the Necrotising Enterocolitis Market’s distributors, traders, and dealers?
Q.6 How are market types and applications and deals, revenue, and value explored?
Q.7 What does a business area’s assessment of agreements, income, and value implicate?
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it